Data set
Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD, with an overall goal to validate biomarkers for use in clinical treatment trials for patients with AD. The study was approved by the Institutional Review Boards at each ADNI site (see full list here: http://adni.loni.usc.edu). Informed consent was obtained from all subjects prior to enrollment. All methods were carried out in accordance with relevant guidelines and regulation. The present study was approved by ADNI Publication Committee (ADNI DPC).
In the present study we included subjects from the ADNI dataset defined as cognitively normal (CN) or as patients with an MCI or AD diagnosis. According to the ADNI protocol, MCI was defined if a…
